AshwinPatkarMDMRCPsych, DFASAM

Psychiatry • Raleigh, NC

Addiction, Pain Medicine, Psychopharmacology

Chief Avance Psychiatry, Adjunct Professor, Psychiatry and Behavioral Sciences, Rush University Medical Center

Join to view full profile

Dr. Patkar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patkar's full profile

Already have an account?

Office
Avance Psychiatry, 7850 Brier Creek Parkway
ste 100
Raleigh, NC 27617
Phone+1 919-748-4878

Fax+1 919-748-4876

Summary

Dr. Ashwin Patkar is a Board Certified psychiatrist in Raleigh, NC. He is Chief, Avance Psychiatry and Adjunct Professor of Psychiatry at Rush University Medical Center. He was previously Professor of Psychiatry at Duke University Medical Center and Medical Director Duke Addictions Program.. He received his medical degree from Seth G.S. Medical College, Mumbai, India and MRCPsych Royal College of Psychiatrists U.K. He is a Distinguished Fellow of APA and ASAM. He has been in practice 30 years. He specializes in addiction, pain medicine, and psychopharmacology. He has more than 275 publications and over 1500 citations.

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Psychiatry, 1995 - 1997
University of NottinghamMPhil, Neuropharmacology, 1993 - 1995
Royal College of PsychiatristsMRCPsych, Psychiatry, 1990 - 1993
Seth G.S. Medical CollegeClass of 1988

Certifications & Licensure

NC State Medical License 2004 - 2025
PA State Medical License 1996 - 2024
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Addiction Psychiatry
American Academy of Pain MedicinePain Medicine
American Society of Addiction MedicineAddiction Medicine

Awards, Honors, & Recognition

Best Doctors in America- Psychiatry Best Doctors, 2009-2020
President North Carolina Society of Addiction Medicine American Society of Addiction Medicine, 2019
Frederick Glaser Award NC American Society of Addiction Medicine, 2017
Distinguished Fellow American Society of Addiction Medicine, 2015
President Indian American Psychiatric Association, 2015
Distinguished Fellow American Psychiatric Association, 2012
Diplomate American Board of Addiction Medicine, 2012
Best Doctors in North Carolina 2009, 2011, 2013
Academician of the Year Award Indian American Psychiatric Association, 2007
Best Paper Award Annual Conference of the American Society of Addiction Medicine, 2002
Jaanssen Research Award for Young Investigators American Academy of Addiction Psychiatry, 1999
Second Annual Pfizer Psychiatry Resident of the Year Award 1997
Lilly Fellowship Award Society of Biological Psychiatry, 1997
Daniel Lieberman Award for best paper by a Jefferson Psychiatry Resident 1997
University Merit Scholarship for Honors
Join now to see all

Clinical Trials

Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome Start of enrollment: 2002 Jan 01
Completed
Phase 4
Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Start of enrollment: 2002 Jan 01
Completed
Phase 4
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS Start of enrollment: 2009 May 01
Completed
Phase 3
Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder Start of enrollment: 2010 Feb 01
Completed
Phase 4
Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone Start of enrollment: 2010 Jul 01
Completed
Phase 3
Open-label, Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation Start of enrollment: 2010 Dec 01
Completed
Phase 1
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose Start of enrollment: 2011 Sep 01
Completed
Phase 3
Major Depressive Disorder With Mixed Features - Extension Start of enrollment: 2011 Sep 01
Completed
Phase 3
Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial Start of enrollment: 2011 Jul 01
Completed
Phase 3
Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone Start of enrollment: 2012 Dec 01
Completed
Phase 3
Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD Start of enrollment: 2017 Jan 23
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting.
Seung-Hoon Lee, Kyung Ho Lee, Tae Sun Han, Changsu Han, Won-Myong Bahk
Clinical Psychopharmacology and Neuroscience. 2024-05-31
Effect of Frailty on Depression among Patients with Late-life Depression: A Test of Anger, Anxiety, and Resilience as Mediators.
Junhyung Kim, Hyun-Ghang Jeong, Moon-Soo Lee, Chi-Un Pae, Ashwin A Patkar
Clinical Psychopharmacology and Neuroscience. 2024-05-31
Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting.
Kyung Ho Lee, Tae Sun Han, Changsu Han, Won-Myong Bahk, Soo-Jung Lee
Clinical Psychopharmacology and Neuroscience. 2023-08-31

Journal Articles

Vitamin D deficiency and psychiatric illness
Harris HW, Jaiswal P, Holmes V, Weisler RH, Patkar AA, Current Psychiatry, 1/1/2013
Case-control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder
Crisafulli C, Shim DS, Andrisano C, Pae CU, Chiesa A, Han C, Patkar AA, Lee SJ, Serretti A, De Ronchi D, Psychiatry Res, 1/2/2012
A review of clinical trial data and clinical implications
Wang SM, Han C, Lee SJ, Patkar AA, Pae CU, Fleischhacker WW Paliperidone, Clin Drug Investig, 1/1/2012
DAOA variants on diagnosis and response to treatment in patients with major depressive disorder and bipolar disorder
Chiesa A, Pae CU, Procelli S, Han C, Lee SJ, Patkar AA, Park MH, Jun TY, Serretti A, J Int Med Res, 1/1/2012
Predictors of Response to Ziprasidone: Results from a 6-Week Randomized Double-Blind, Placebo-Controlled Trial for Acute depressive Mixed State
Pae CU, Patkar AA, Gilmer W, Holtzman N, Thommi SB, Ghaemi SN, Pharmacopsychiatry, 1/1/2012
The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal
Mannelli P, Peindl K, Wu LT, Patkar AA, Gorelick DA, AM J Drug Alcohol Abuse, 1/1/2012
An integrated alcohol abuse and medical treatment model for patients with hepatitis C
Proeschold-Bell RJ, Patkar AA, Naggie S, Coward L, Mannelli P, Yao J, Bixby P, Muir AJ, Dig Dis Sci, 1/1/2012
Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variations rs10042486 on schizophrenia and response to antipsychotics
Crisafulli C, Chiesa A, Han C, Lee SJ, Park MH, Balzarro B, Andrisano C, Patkar AA, Pae CU, Serretti A, Eur Arch Psychiatry Clin Neurosci, 1/1/2012
Influence of BDNF cariants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia
Pae CU, Chiesa A, Porcelli S, Han C, Patkar AA, Lee SJ, Park MH, Serretti A, De Ronchi D, Neuropsychobiology, 1/1/2012
Influence of GRIA1, GRIA2, and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder
Chiesa A, Crisafulli C, Porcelli S, Han C, Patkar AA, Lee SJ, Park MH, Jun TY, Serretti A, Pae CU, Eur Arch Psychiatry Clin Neurosci, 1/5/2011
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study
Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS, Clin Psychiatry, 1/1/2010
HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study
Meade CS, Weiss RD, Fitzmaurice GM, Poole SA, Subramaniam GA, Patkar AA, Connery HS, Woody GE, Acquir Immune Defic Syndr, 1/1/2010
Paroxetine mesylate: comparable to paroxetine hydrochloride? Expert Opin Pharmacother
Pae CU, Misra A, Ham BJ, Han C, Patkar AA, Masand PS, Expert Opin Pharmacother, 1/1/2010
Diagnosis and Treatment of Opioid Dependence
Patkar AA, Bhatia K, Lee J, BMJ Point of Care, 1/1/2009
Psychometric properties of the patient Health Questionnaire- 15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients
Han C, Pae CU, Patkar AA, Masand PS, Kim KW, Joe SH, Jung IK, Psychosomatics, 1/1/2009
Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain
Langley PC, Patkar AA, Boswell KA, Benson CJ, Schein JR, Curr Med Res Opin, 1/1/2009
Opioid use affects antioxidant activity and purine metabolism: preliminary results
Mannelli P, Patkar AA, Rozen S, Matson W, Krishnan R, Kaddurah-Daouk R, Human Psychopharmacology, 1/1/2009
Methylphenidate extended release (OROS MPH) for the treatment of antidepressant- related sexual dysfunction in patients with treatment-resistant depression: results fr...
Pae CU, Marks DM, Masand PS, Peindl K, Hooper-Wood C, Han C, Mannelli P, Ciccone P, Patkar AA, Clin Neuropharmacol, 1/1/2009
History of early abuse as a predictor of treatment response in patients with fibromyalgia: post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled...
Pae CU, Masand PS, Marks DM, Krulewicz S, Han C, Peindl K, Mannelli P, Patkar AA, World J Biol Psychiatry, 1/1/2009
Short-, intermediate-, and long-term outcomes of Pennsylvania's continuum of tobacco education pilot project
Leone FT, Evers-Casey S, Veloski J, Patkar AA, Kanzleiter L, Pennsylvania continuum of tobacco education work shop, Nicotine and Tobacco Research, 1/1/2009
A randomized, double-blind, placebo-controlled trial of controlled release paroxetine in Irritable Bowel Syndrome
Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia I, Patkar AA, Psychosomatic Medicine, 1/1/2009
Infrequent illicit methadone use among stimulant- using patients in methadone maintenance treatment programs: a national drug abuse treatment clinical trials network
Wu LT, Blazer DG, Stitzer ML, Patkar AA, Blaine JD, Am J Addict, 1/1/2008
A case of transient hallucination with ropinirole augmentation in a patient with treatment-resistant depression: is there differential effect of ropinirole dose on dev...
Pae CU, Marks DM , Han C, Patkar AA, Progress in Neuropsychopharmacology and Biological Psychiatry, 1/1/2008
Delirium: Underrecognized and Undertreated
Pae CU, Marks DM, Han C, Patkar AA, Masand P, Curr Treat Options Neurol, 1/1/2008
The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double- blind, placebo-control...
Pae CU, Lim HK, Peindl K, Ajwani N, Serretti A, Patkar AA, Lee C, Int Clin Psychopharmacol, 1/1/2008
Join now to see all

Books/Book Chapters

Interventions for Addiction: Comprehensive Addictive Behaviors and Disorders
Chapter: Medication for Cravings in Substance Use Disorders
Page 527 - 542Patkar, A.A., Lee, J.C., Burgess, D.M.Editors: Miller P.Elsevier Inc., Academic Press, San Diego, CA2013
Guide to Assessment Scales in Schizophrenia
Chapter: Rating Scales for Substance Abuse
Page 181 - 187Patkar AA & Lee JCEditors: Keefe R.Springer Health Care, New York, NY2012
Pharmacology and Therapeutics. From Principles to Practice
Chapter: Neuropharmacology of Anxiety Disorders
Pae Chi-un and Patkar AAEditors: Waldman SA and Terzic A.Elsevier, New York, NY2008
Textbook of Consultation-Liaison Psychiatry
Chapter: Mania, Catatonia, & Psychosis in the Medically Ill
Masand PS, Christopher E, Clary GS, Mago RM, Patkar AAAmerican Psychiatric Press, Washington, DC2004
Join now to see all

Abstracts/Posters

Serotonin transporter gene polymorphisms in cocaine dependence
ll KP, Patkar AA, Berrettini WH, Gottheil E, Wendel B, Sterling RC and Weinstein SP, AMIS-PHL Student Poster Competition, Philadelphia, PA, 1/1/1999

Lectures

Urinary concentrations of buprenorphine and norbuprenorphine as indicators of noncompliance and diversion.
Austin, TX - 1/23/2015
Brain Music Therapy for insomnia and anxiety in Addiction Treatment.
Austin, TX - 1/23/2015
Screening and Brief Intervention for substance abuse in patients with Hepatitis C.
Duke University Health Center - 1/18/2015
Strategies for treatment of opioid addiction.
Raleigh, NC - 1/17/2015
Resilience and Recovery in Substance Abuse Treatment.
Point Clear, AL - 1/15/2015
Screening and Brief Intervention training for students and Professionals.
Southern Heath Area Education Center, Fayetteville, NC - 1/13/2015
Early Improvement with augmentation for major depressive disorder: A fresh look at the evidence.
Qingdao, China - 1/25/2014
Management of psychiatric comorbidity in substance use disorders.
Asheville, NC - 1/22/2014
An integrated framework to managing chronic pain, mental illness and substance abuse.
Raleigh, NC - 1/17/2014
Substance use disorders in DSM-5. Revisions and Rationale
Pune, India - 1/16/2014
Effects of milnacipran on pain and sexual function and in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial.
Hollywood, FL - 1/16/2014
Project Lazarus: Chronic pain initiative in North Carolina
Wilmington, NC, 2013; Durham, NC, 2014; Henderson, NC, 2014 - 1/14/2014
Effects of milnacipran on neurocognition and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial.
New York, NY - 1/3/2014
F-MRI changes in a randomized controlled trial of ondansetron-methylphenidate combination in stimulant dependence.
New York, NY - 1/3/2014
Early improvement with vilazodone in adults with major depressive disorder. A post-hoc analysis of a randomized, double-blind, placebo-controlled trial.
New York, NY - 1/3/2014
Three Different Dose Initiation Strategies With Vilazodone In Major Depressive Disorder: A 8-Week Randomized, Double-Blind Trial Comparing Safety And Tolerability Of S...
New York, NY - 1/3/2014
Lisdexamphetamine dimesylate augmentation in major depressive disorder: Post hoc item analysis of residual symptoms on the QIDS-SR in clinician rated remitters and non...
Hollywood, FL - 1/28/2013
Milnacipran, neurocognition and fatigue in fibromyalgia: A double blind, randomized 13-week crossover trial.
San Francisco, CA - 1/18/2013
Posthoc analysis of lisdexamphetamine dimesylate augmentation therapy effects on sleep related endpoints in adults with major depressive disorder.
San Francisco, CA - 1/18/2013
Lisdexamphetamine dimesylate augmentation in anxious or nonanxious major depressive disorder.
San Francisco, CA - 1/18/2013
Lisdexamphetamine dimesylate augmentation effects on executive function in major depressive disorder based on level of executive function impairment.
San Francisco, CA - 1/16/2013
Screening and Brief Interventions for Substance Abuse
Multiple Locations, 2011, 2013 - 1/12/2013
Mitigating Misuse and Abuse of Prescription Stimulants
Asheville, NC - 1/12/2013
Chronic pain initiative in North Carolina
Gastonia, NC - 1/10/2013
A proof-of-concept bench-to-bedside project.
Seoul, Republic of Korea - 1/6/2013
Join now to see all

Other

Opioid Use disorder
Patkar, A.A., Lee, J.C., Burgess, D.M., Disease State Management. Epocrates online. Athena Health, BMJ Publishing group
London, United Kingdom - 1/1/2012